Get the Stockscreener App
34.07
2.53%
0.84
After Hours:
34.07
Harmony Biosciences Holdings Inc stock is traded at $34.07, with a volume of 489.15K.
It is up +2.53% in the last 24 hours and down -2.27% over the past month.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
See More
Previous Close:
$33.23
Open:
$33.17
24h Volume:
489.15K
Relative Volume:
0.71
Market Cap:
$1.91B
Revenue:
$681.88M
Net Income/Loss:
$122.63M
P/E Ratio:
13.85
EPS:
2.46
Net Cash Flow:
$220.18M
1W Performance:
+2.57%
1M Performance:
-2.27%
6M Performance:
+12.85%
1Y Performance:
+19.54%
1-Day Range:
$32.90
$34.17
1-Week Range:
$32.33
$34.17
52-Week Range:
$28.14
$41.61
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Name
Harmony Biosciences Holdings Inc
Sector
Industry
Phone
(484) 539-9800
Address
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| HRMY | 34.07 | 1.91B | 681.88M | 122.63M | 220.18M | 2.46 |
| VRTX | 450.97 | 116.38B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 82.09B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.14B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.25B | 3.30B | -501.07M | 1.03B | 11.54 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-21-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-25-23 | Downgrade | Goldman | Neutral → Sell |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-20-23 | Initiated | BofA Securities | Neutral |
| Oct-14-22 | Upgrade | Janney | Neutral → Buy |
| Oct-14-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-03-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-04-21 | Initiated | Raymond James | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Mar-29-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-14-20 | Initiated | Goldman | Neutral |
| Sep-14-20 | Initiated | Jefferies | Buy |
| Sep-14-20 | Initiated | Piper Sandler | Overweight |
View All
Harmony Biosciences Holdings Inc Stock (HRMY) Latest News
Pacer Advisors Inc. Decreases Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES - Lelezard
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES – Company Announcement - Financial Times
Harmony Biosciences Reports Record Revenue and Plans Expansion in CNS Treatments - MSN
HRMY (Harmony Biosciences Holdings) GF Value Rank : 4 (As of Nov. 20, 2024) - GuruFocus.com
Principal Financial Group Inc. Sells 19,654 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
Quest Partners LLC Acquires 20,689 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
First Week of July 2025 Options Trading For Harmony Biosciences Holdings (HRMY) - Nasdaq
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Sees Significant Drop in Short Interest - MarketBeat
14,396 Shares in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Purchased by CWA Asset Management Group LLC - MarketBeat
Harmony Biosciences’ Common Stock Offering - Global Legal Chronicle
Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points (NASDAQ:HRMY) - Seeking Alpha
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Harmony Biosciences director Antonio Gracias sells $139m in stock - Investing.com India
Marshman Fund Trust II sells $139.39 million in Harmony Biosciences stock - Investing.com
Harmony Biosciences director Antonio Gracias sells $139m in stock By Investing.com - Investing.com UK
AlphaCentric Advisors LLC Has $3.88 Million Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
There May Be Some Bright Spots In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings - Yahoo Canada Finance
Top 5 US Stocks To Buy In November 2024 - Investing.com
HRMY vs. REGN: Which Stock Is the Better Value Option? - MSN
(HRMY) Trading Signals - Stock Traders Daily
Harmony Biosciences Holdings Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Earnings Beat: Harmony Biosciences Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now? - Yahoo Finance
Harmony Bio, The No. 1 Biotech Stock, Surges On Its 'High Quality' Beat - MSN
Harmony Biosciences Holdings Prices of Public Offering of Common Stock - citybiz
Harmony Biosciences chief commercial officer sells $870,018 in stock - Investing.com India
Harmony Biosciences chief commercial officer sells $870,018 in stock By Investing.com - Investing.com Canada
Latham Advises Harmony Biosciences Holdings, Inc. in Public Offering of Common Stock by Selling Shareholders - Latham & Watkins LLP
HRMY Makes Notable Cross Below Critical Moving Average - Nasdaq
Harmony Biosciences (NASDAQ:HRMY) Sees Strong Trading Volume Following Analyst Upgrade - MarketBeat
Cantor Fitzgerald Issues Positive Estimate for HRMY Earnings - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q3 2024 Earnings Call Transcript - Insider Monkey
Harmony Biosciences Holdings, Inc. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next - Simply Wall St
Goldman Sachs maintains sell rating on HRMY stock with $28 target - Investing.com Canada
Harmony Biosciences Holdings Inc (HRMY) Q3 2024 Earnings Call Hi - GuruFocus.com
Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders - StockTitan
Harmony’s Wakix Surpasses $2B in Revenue, Data Shows Promise for IH Treatment - Sleep Review
Goldman Sachs maintains sell rating on HRMY stock with $28 target By Investing.com - Investing.com South Africa
Cantor Fitzgerald Raises Harmony Biosciences (NASDAQ:HRMY) Price Target to $58.00 - MarketBeat
Harmony Biosciences' (HRMY) "Outperform" Rating Reaffirmed at Oppenheimer - MarketBeat
Harmony Biosciences: Strong Q3 and Future Growth - MSN
Harmony Biosciences (NASDAQ:HRMY) Releases Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Shares Gap DownHere's Why - MarketBeat
Is Harmony Biosciences Holdings (NASDAQ:HRMY) Using Too Much Debt? - Simply Wall St
Harmony Biosciences stock hits 52-week high at $40.73 By Investing.com - Investing.com Australia
Axonis Therapeutics Announces $115 Million Series A Financing - Quantisnow
Goldman Sachs Reiterates Sell Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider.com
Harmony Biosciences Holdings Inc (HRMY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth ... - Investing.com Canada
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUA - GuruFocus.com
Harmony Biosciences initiates public stock offering by shareholders By Investing.com - Investing.com South Africa
Harmony Biosciences Holdings Inc Stock (HRMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):